Published in Vaccine Weekly, September 7th, 1998
Highly active antiretroviral therapy (HAART) - now the standard of care for the industrialized world - has greatly reduced AIDS incidence. And while HAART isn't cheap, its cost is far less than the cost of treating AIDS.
"HAART is arguably the most cost-effective major new medical technology that has been introduced in the past decade," say John G. Bartlett and colleagues.
The Johns Hopkins researchers reported the results of a cost/effect study of HAART in clinical practice at the 12th World AIDS Conference, held June 28-July 3, 1998, in Geneva, Switzerland.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly